<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864095</url>
  </required_header>
  <id_info>
    <org_study_id>Hip blood</org_study_id>
    <nct_id>NCT02864095</nct_id>
  </id_info>
  <brief_title>The Effects of Low-dose Epinephrine Plus Tranexamic Acid on Perioperative Haemostasis and Inflammatory Reaction in Major Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the blood loss of intravenous and topical
      administration of low dose epinephrine plus combined administration of intravenous and
      topical tranexamic acid for primary total hip arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss on post-operative day 1</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with infection</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deep vein thrombosis cases</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pulmonary embolism cases</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of plexus venosus leg muscle thrombosis</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of IL-10（Preoperation, intraoperation and post-operation）</measure>
    <time_frame>Preoperation, intraoperation and up to 2 days post-operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of IL-6（Preoperation, intraoperation and post-operation）</measure>
    <time_frame>Preoperation, intraoperation and up to 2 days post-operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of IL-1β（Preoperation, intraoperation and post-operation）</measure>
    <time_frame>Preoperation, intraoperation and up to 2 days post-operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of TNF-α（Preoperation, intraoperation and post-operation）</measure>
    <time_frame>Preoperation, intraoperation and up to 2 days post-operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin (Hb)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit (Hct)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (PLT)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss on post-operative day 3</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperation, intraoperation and post-operation R value (min) of thrombelastogram</measure>
    <time_frame>Preoperation, intraoperation and up to 2 days post-operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperation, intraoperation and post-operation K value (min) of thrombelastogram</measure>
    <time_frame>Preoperation, intraoperation and up to 2 days post-operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperation, intraoperation and post-operation Angle (deg) of thrombelastogram</measure>
    <time_frame>Preoperation, intraoperation and up to 2 days post-operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperation, intraoperation and post-operation MA (mm) of thrombelastogram</measure>
    <time_frame>Preoperation, intraoperation and up to 2 days post-operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperation, intraoperation and post-operation comprehensive index of blood clotting (CI) of thrombelastogram</measure>
    <time_frame>Preoperation, intraoperation and up to 2 days post-operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperation, intraoperation and post-operation LY30 (%) of thrombelastogram</measure>
    <time_frame>Preoperation, intraoperation and up to 2 days post-operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with blood transfusion</measure>
    <time_frame>7 days</time_frame>
    <description>Number of transfusion cases, number of units transfused and amount of transfusion</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Intravenous epinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) low dose epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical epinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No epinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid (TXA)</intervention_name>
    <description>IV and topical administration</description>
    <arm_group_label>Intravenous epinephrine</arm_group_label>
    <arm_group_label>Topical epinephrine</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <arm_group_label>Intravenous epinephrine</arm_group_label>
    <arm_group_label>Topical epinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients between the ages of 20 and 75 who were diagnosed with as having
             osteoarthritis or osteonecrosis of the femoral head

          -  Scheduled for an elective primary total hip arthroplasty

          -  Those who were willing and able to return for follow-up over at least a 6-month
             postoperative period

        Exclusion Criteria:

          -  Acute coronary syndrome &lt; 6 months

          -  Glaucoma,pheochromocytoma, thyrotoxicosis, digoxin intoxication, serum potassium &lt; 3.0
             mmol, alcohol abuse, premenopausal women

          -  Current treatment with adenosine diphosphate (ADP) receptor antagonists, Factor Xa or
             thrombin inhibitors,heparin (excluding Low Molecular Weight Heparin (LMWH) for
             perioperative thromboprophylaxis), tricyclic antidepressants, or monoamine
             oxidase（MAO) or Catechol-O-methyltransferase (COMT) inhibitors

          -  Patients with history of thromboembolic disease, bleeding disorder

          -  Patients with history of renal impairment, cardiovascular diseases (previous
             myocardial infarction, atrial fibrillation ) or cerebrovascular conditions (previous
             stroke or peripheral vascular surgery)

          -  Allergy to TXA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weinan Zeng, doctor</last_name>
      <phone>+8615023100103</phone>
      <email>weinanzeng@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>Liu Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Arthroplasty, Replacement, Hip</keyword>
  <keyword>Epinephrine</keyword>
  <keyword>Tranexamic acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

